Multiple Infectious Agents and the Origins of Atherosclerotic Coronary Artery Disease

Frontiers in Cardiovascular Medicine

Volumn 3, Issue , 2016, Pages

  Lawson, James S ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

atherosclerosis; coronary atheroma; coronary disease; diet and nutrition; infectious pathogens; trends

Indexed keywords

EID: 85024385599     PISSN: None     EISSN: 2297055X     Source Type: Journal    
DOI: 10.3389/fcvm.2016.00030     Document Type: Review

References (100)

1. Libby P. Inflammation in atherosclerosis. Nature (2002) 420:868–74.10.1038/nature0132312490960
2. Stary HC. Lipid and macrophage accumulations in arteries of children and the development of atherosclerosis. Am J Clin Nutr (2000) 72(5 Suppl):1297S–306S.11063472
3. Milei J, Ottaviani G, Lavezzi AM, Grana DR, Stella I, Matturri L. Perinatal and infant early atherosclerotic coronary lesions. Can J Cardiol (2008) 24:137–41.10.1016/S0828-282X(08)70570-118273488
4. Burgner DP, Cooper MN, Moore HC, Stanley FJ, Thompson PL, de Klerk NH, et al. Childhood hospitalisation with infection and cardiovascular disease in early-mid adulthood: a longitudinal population-based study. PLoS One (2015) 10:e0125342.10.1371/journal.pone.012534225938548
5. Burgner DP, Sabin MA, Magnussen CG, Cheung M, Kähönen M, Lehtimäki T, et al. Infection-related hospitalization in childhood and adult metabolic outcomes. Pediatrics (2015) 136:e554–62.10.1542/peds.2015-082526283782
6. Velican D, Velican C. Study of fibrous plaques occurring in the coronary arteries of children. Atherosclerosis (1979) 33:201–5.10.1016/0021-9150(79)90117-5475879
7. Nguyen MU, Wallace MJ, Pepe S, Menheniott TR, Moss TJ, Burgner D. Perinatal inflammation: a common factor in the early origins of cardiovascular disease? Clin Sci (Lond) (2015) 129:769–84.10.1042/CS2015004526223841
8. Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman WP, III Herderick EE, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the pathobiological determinants of atherosclerosis in Youth Study. JAMA (1999) 281:727–35.10.1001/jama.281.8.72710052443
9. Monckeberg JG. Anatomische veranderungen am kreislaufsystem bei kreigsteilnehmern. Zentralbl Herz Gefasskrankheiten (1915) 7:336–43.
10. Enos WF, Beyer JC, Holmes RH. Pathogenesis of coronary disease in American soldiers killed in Korea. JAMA (1955) 158:912–4.10.1001/jama.1955.02960110018005
11. McNamara JJ, Molot MA, Stremple JF, Cutting RT. Coronary artery disease in combat casualties in Vietnam. JAMA (1971) 216:1185–7.10.1001/jama.216.7.1185
12. Webber BJ, Seguin PG, Burnett DG, Clark LL, Otto JL. Prevalence of and risk factors for autopsy-determined atherosclerosis among US service members, 2001-2011. JAMA (2012) 308:2577–83.10.1001/jama.2012.7083023268516
13. Lawson JS, Glenn WK, Tran DD, Ngan CC, Duflou JA, Whitaker NJ. Identification of human papilloma viruses in atheromatous coronary artery disease. Front Cardiovasc Med (2015) 2:17.10.3389/fcvm.2015.0001726664889
14. National Heart, Lung and Blood Institute (NHLBI). Disease Statistics in NHLBI Fact Book. Bethesda: National Institutes of Health (2014).
15. Nemetz PN, Smith CY, Bailey KR, Roger VL, Edwards WD, Leibson CL. Trends in coronary atherosclerosis: a tale of two population subgroups. Am J Med (2016) 129:307–14.10.1016/j.amjmed.2015.10.03226551982
16. Vital Statistics of the United States, National Center for Health Statistics. Health, United States. Hyattsville, MD (2014).
17. Booze CF, Staggs CM. A comparison of post-mortem atherosclerosis findings in general aviation plot fatalities. Aviat Space Environ Med (1987) 58:297–300.
18. Roger VL, Weston SA, Killian JM, Pfeifer EA, Belau PG, Kottke TE, et al. Time trends in the prevalence of atherosclerosis: a population-based autopsy study. Am J Med (2001) 110:267–73.10.1016/S0002-9343(00)00709-911239844
19. Newman WP, Guzman MA, Strong JP, Tracy RE, Oalmann MC. Secular trends in atherosclerotic lesions: comparison of two studies of autopsied men conducted in different time periods. Mod Pathol (1988) 1:109–13.3237694
20. Nemetz PN, Roger VL, Ransom JE, Bailey KR, Edwards WD, Leibson CL. Recent trends in the prevalence of coronary disease: a population-based autopsy study of nonnatural deaths. Arch Intern Med (2008) 168:264–70.10.1001/archinternmed.2007.7918268166
21. Mirzaei M, Truswell AS, Taylor R, Leeder SR. Coronary heart disease epidemics: not all the same. Heart (2009) 95:740–6.10.1136/hrt.2008.15485619095711
22. Kannel WB, Schwartz MJ, McNamara PM. Blood pressure and risk of coronary heart disease: the Framingham study. Dis Chest (1969) 56:43–52.10.1378/chest.56.1.43
23. Yatsuya H, Li Y, Hilawe EH, Ota A, Wang C, Chiang C, et al. Global trend in overweight and obesity and its association with cardiovascular disease incidence. Circ J (2014) 78:2807–18.10.1253/circj.CJ-14-085025391910
24. Fabricant CG, Fabricant J, Litrenta MM, Minick CR. Virus-induced atherosclerosis. J Exp Med (1978) 148:335–40.10.1084/jem.148.1.335209124
25. Fabricant CG, Hajjar DP, Minick CR, Fabricant J. Herpesvirus infection enhances cholesterol and cholesteryl ester accumulation in cultured arterial smooth muscle cells. Am J Pathol (1981) 105:176–84.6271018
26. Fabricant CG, Fabricant J. Atherosclerosis induced by infection with Marek’s disease herpesvirus in chickens. Am Heart J (1999) 138(5 Pt 2):S465–8.10.1016/S0002-8703(99)70276-010539849
27. Ibrahim AI, Obeid MT, Jouma MJ, Moasis GA, Al-Richane WL, Kindermann I, et al. Detection of herpes simplex virus, cytomegalovirus and Epstein-Barr virus DNA in atherosclerotic plaques and in unaffected bypass grafts. J Clin Virol (2005) 32:29–32.10.1016/j.jcv.2004.06.01015572003
28. Reszka E, Jegier B, Wasowicz W, Lelonek M, Banach M, Jaszewski R. Detection of infectious agents by polymerase chain reaction in human aortic wall. Cardiovasc Pathol (2008) 17:297–302.10.1016/j.carpath.2007.11.00218402822
29. Hsu HY, Nicholson AC, Pomerantz KB, Kaner RJ, Hajjar DP. Altered cholesterol trafficking in herpesvirus-infected arterial cells. Evidence for viral protein kinase-mediated cholesterol accumulation. J Biol Chem (1995) 270:19630–7.10.1074/jbc.270.33.196307642651
30. Apostolou F, Gazi IF, Lagos K, Tellis CC, Tselepis AD, Liberopoulos EN, et al. Acute infection with Epstein-Barr virus is associated with atherogenic lipid changes. Atherosclerosis (2010) 212:607–13.10.1016/j.atherosclerosis.2010.06.00620594556
31. Gargouri B, Nasr R, Mseddi M, Benmansour R, Lassoued S. Induction of Epstein-Barr virus (EBV) lytic cycle in vitro causes lipid peroxidation, protein oxidation and DNA damage in lymphoblastoid B cell lines. Lipids Health Dis (2011) 10:111.10.1186/1476-511X-10-11121722381
32. Fan J, Zhang W, Liu Q. Human cytomegalovirus-encoded miR-US25-1 aggravates the oxidised low density lipoprotein-induced apoptosis of endothelial cells. Biomed Res Int (2014) 2014:531979.10.1155/2014/53197924895586
33. Armingohar Z, Jørgensen JJ, Kristoffersen AK, Abesha-Belay E, Olsen I. Bacteria and bacterial DNA in atherosclerotic plaque and aneurysmal wall biopsies from patients with and without periodontitis. J Oral Microbiol (2014) 6.10.3402/jom.v6.2340825006361
34. Mitra S, Drautz-Moses DI, Alhede M, Maw MT, Liu Y, Purbojati RW, et al. In silico analyses of metagenomes from human atherosclerotic plaque samples. Microbiome (2015) 3:38.10.1186/s40168-015-0100-y26334731
35. Popović M, Smiljanić K, Dobutović B, Syrovets T, Simmet T, Isenović ER. Human cytomegalovirus infection and atherothrombosis. J Thromb Thrombolysis (2012) 33:160–72.10.1007/s11239-011-0662-x22161772
36. Post WS, Budoff M, Kingsley L, Palella FJ, Jr Witt MD, Li X, et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med (2014) 160:458–67.10.7326/M13-175424687069
37. Mahendra J, Mahendra L, Nagarajan A, Mathew K. Prevalence of eight putative periodontal pathogens in atherosclerotic plaque of coronary artery disease patients and comparing them with noncardiac subjects: a case-control study. Indian J Dent Res (2015) 26:189–95.10.4103/0970-9290.15916426096116
38. Kuo HK, Fujise K. Human papillomavirus and cardiovascular disease among U.S. women in the National Health and Nutrition Examination Survey, 2003 to 2006. J Am Coll Cardiol (2011) 58:2001–6.10.1016/j.jacc.2011.07.03822032713
39. Bonin LR, Madden K, Shera K, Ihle J, Matthews C, Aziz S, et al. Generation and characterization of human smooth muscle cell lines derived from atherosclerotic plaque. Arterioscler Thromb Vasc Biol (1999) 19:575–87.10.1161/01.ATV.19.3.57510073960
40. Pigarevskii PV, Mal’tseva SV, Snegova VA, Davydova NG, Guseva VA. Chlamydia pneumoniae and immunoinflammatory reactions in an unstable atherosclerotic plaque in humans. Bull Exp Biol Med (2015) 159(2):278–81.10.1007/s10517-015-2941-626085364
41. Sakurai-Komada N, Iso H, Koike KA, Ikeda A, Umesawa M, Ikehara S, et al. Association between Chlamydophila pneumoniae infection and risk of coronary heart disease for Japanese: the JPHC study. Atherosclerosis (2014) 233:338–42.10.1016/j.atherosclerosis.2014.01.02324530959
42. Sorrentino R, Yilmaz A, Schubert K, Crother TR, Pinto A, Shimada K, et al. A single infection with Chlamydia pneumoniae is sufficient to exacerbate atherosclerosis in ApoE deficient mice. Cell Immunol (2015) 294:25–32.10.1016/j.cellimm.2015.01.00725666507
43. Kwon TW, Kim DK, Ye JS, Lee WJ, Moon MS, Joo CH, et al. Detection of enterovirus, cytomegalovirus, and Chlamydia pneumoniae in atheromas. J Microbiol (2004) 42(4):299–304.15650686
44. Kimura H. Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol (2006) 16:251–61.10.1002/rmv.50516791843
45. Serino M, Blasco-Baque V, Nicolas S, Burcelin R. Far from the eyes, close to the heart: dysbiosis of gut microbiota and cardiovascular consequences. Curr Cardiol Rep (2014) 16:540.10.1007/s11886-014-0540-125303894
46. Koren O, Spor A, Felin J, Fak F, Stombaugh J, Tremaroli V, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A (2011) 108(Suppl):45924598.10.1073/pnas.101138310720937873
47. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol (2015) 21:8787–803.10.3748/wjg.v21.i29.878726269668
48. Azad MB, Konya T, Persaud RR, Guttman DS, Chari RS, Field CJ, et al. Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study. BJOG (2016) 123:983–93.10.1111/1471-0528.1360126412384
49. Berkhout B. With a little help from my enteric microbial friends. Front Med (2015) 2:30.10.3389/fmed.2015.0003026029695
50. Marmot MG, Syme SL. Acculturation and coronary heart disease in Japanese-Americans. Am J Epidemiol (1976) 104:225–47.961690
51. Truett J, Cornfield J, Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham. J Chronic Dis (1967) 20:511–24.10.1016/0021-9681(67)90082-3
52. Keys A, editor. Coronary heart disease in 7 countries. Circulation (1970) 41(Suppl):1–198.
53. Dawber DA, Kannel WB, Revotskie N, Kagan A. The epidemiology of coronary heart disease – the Framingham enquiry. Proc R Soc Med (1962) 55:265–71.
54. Sharpe LJ, Cook EC, Zelcer N, Brown AJ. The UPS and downs of cholesterol homeostasis. Trends Biochem Sci (2014) 39:527–35.10.1016/j.tibs.2014.08.00825220377
55. Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med (2014) 160:398–406.10.7326/M13-178824723079
56. Astrup A. A changing view on saturated fatty acids and dairy: from enemy to friend. Am J Clin Nutr (2014) 100:1407–8.10.3945/ajcn.114.099986
57. de Souza RJ, Mente A, Maroleanu A, Cozma AI, Ha V, Kishibe T, et al. Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ (2015) 351:h3978.10.1136/bmj.h397826268692
58. Berger S, Raman G, Vishwanathan R, Jacques PF, Johnson EJ. Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr (2015) 102:276–94.10.3945/ajcn.114.10030526109578
59. Hooper L, Martin N, Abdelhamid A, Davey Smith G. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev (2015) (6):CD011737.10.1002/14651858.CD01173726068959
60. Twig G, Yaniv G, Levine H, Leiba A, Goldberger N, Derazne E, et al. Body-mass index in 2.3 million adolescents and cardiovascular death in adulthood. N Engl J Med (2016) 374:2430–40.10.1056/NEJMoa150384027074389
61. FAO Statistics. Food Consumption Tables and Food Balance Sheets. Rome: Food and Agriculture Organisation of the United Nations (1954–2015).
62. World Health Organization. World Health Statistics Annuals 1995. Geneva (2015).
63. Marmot MG, Syme SL, Kagan A, Kato H, Cohen JB, Belsky J. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: prevalence of coronary and hypertensive heart disease and associated risk factors. Am J Epidemiol (1975) 102:514–25.1202953
64. Choudhury SR. Curb5 for the INTERLIPID Research Group differences in cardiovascular disease risk factors between Japanese in Japan and Japanese-Americans in Hawaii: the INTERLIPID study. J Hum Hypertens (2003) 17:631–9.10.1038/sj.jhh.1001606
65. Epstein SE, Zhu J, Najafi AH, Burnett MS. Insights into the role of infection in atherogenesis and in plaque rupture. Circulation (2009) 119:3133–41.10.1161/CIRCULATIONAHA.109.849455
66. Campbell LA, Rosenfeld ME. Infection and atherosclerosis development. Arch Med Res (2015) 46:339–50.10.1016/j.arcmed.2015.05.00626004263
67. Feingold KR, Grunfeld C. The Effect of Inflammation and Infection on Lipids and Lipoproteins. ENDOTEXT. South Dartmouth, MA: MDText.com, Inc. (2000–2015).
68. Clifford A, Hoffman GS. Evidence for a vascular microbiome and its role in vessel health and disease. Curr Opin Rheumatol (2015) 27:397–405.10.1097/BOR.000000000000018426002032
69. Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science (1994) 265:391–4.10.1126/science.80231608023160
70. Fan T, Lu H, Hu H, Shi L, McClarty GA, Nance DM, et al. Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation. J Exp Med (1998) 187:487–96.10.1084/jem.187.4.4879463399
71. Zhou YF, Guetta E, Yu ZX, Finkel T, Epstein SE. Human cytomegalovirus increases modified low density lipoprotein uptake and scavenger receptor mRNA expression in vascular smooth muscle cells. J Clin Invest (1996) 98:2129–38.10.1172/JCI1190198903333
72. Brodala N, Merricks EP, Bellinger DA, Damrongsri D, Offenbacher S, Beck J, et al. Porphyromonas gingivalis bacteremia induces coronary and aortic atherosclerosis in normocholesterolemic and hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol (2005) 25:1446–51.10.1161/01.ATV.0000167525.69400.9c15845905
73. Turkay C, Saba R, Sahin N, Altunbas H, Ozbudak O, Akkaya B, et al. Effect of chronic Pseudomonas aeruginosa infection on the development of atherosclerosis in a rat model. Clin Microbiol Infect (2004) 10:705–8.10.1111/j.1469-0691.2004.01048.x15301672
74. Gurven M, Kaplan H, Winking J, Eid Rodriguez D, Vasunilashorn S, Kim JK, et al. Inflammation and infection do not promote arterial aging and cardiovascular disease risk factors among lean horticulturalists. PLoS One (2009) 4:e6590.10.1371/journal.pone.000659019668697
75. Vasunilashorn S, Crimmins EM, Kim JK, Winking J, Gurven M, Kaplan H, et al. Blood lipids, infection, and inflammatory markers in the Tsimane of Bolivia. Am J Hum Biol (2010) 22:731–40.10.1002/ajhb.2107420721985
76. Low H, Cheng L, Di Yacovo MS, Churchill MJ, Meikle P, Bukrinsky M, et al. Lipid metabolism in patients infected with Nef-deficient HIV-1 strain. Atherosclerosis (2016) 244:22–8.10.1016/j.atherosclerosis.2015.10.10326581048
77. Sun S, Cheng B, Wu X, Wu Q, Qi B, Wu J, et al. Chlamydia pneumoniae disrupts lipid metabolism in human umbilical vein endothelial cells. Mol Med Rep (2014) 10:1150–6.10.3892/mmr.2014.229524898283
78. Bobryshev YV, Killingsworth MC, Tran D, Lord R. Amalgamation of Chlamydia pneumoniae inclusions with lipid droplets in foam cells in human atherosclerotic plaque. Virchows Arch (2008) 453:69–77.10.1007/s00428-008-0629-218528704
79. Stehr M, Elamin AA, Singh M. Cytosolic lipid inclusions formed during infection by viral and bacterial pathogens. Microbes Infect (2012) 14:1227–37.10.1016/j.micinf.2012.08.00122982567
80. Marangoni A, Fiorino E, Gilardi F, Aldini R, Scotti E, Nardini P, et al. Chlamydia pneumoniae acute liver infection affects hepatic cholesterol and triglyceride metabolism in mice. Atherosclerosis (2015) 241:471–9.10.1016/j.atherosclerosis.2015.05.02326086356
81. Chen S, Shimada K, Zhang W, Huang G, Crother TR, Arditi M. IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection-accelerated atherosclerosis in mice. J Immunol (2010) 185:5619–27.10.4049/jimmunol.1001879
82. Maekawa T, Takahashi N, Tabeta K, Aoki Y, Miyashita H, Miyauchi S, et al. Chronic oral infection with Porphyromonas gingivalis accelerates atheroma formation by shifting the lipid profile. PLoS One (2011) 6:e20240.10.1371/journal.pone.002024021625524
83. Li XY, Wang C, Xiang XR, Chen FC, Yang CM, Wu J. Porphyromonas gingivalis lipopolysaccharide increases lipid accumulation by affecting CD36 and ATP-binding cassette transporter A1 in macrophages. Oncol Rep (2013) 30:1329–36.10.3892/or.2013.260023835648
84. Kempe S, Heinz P, Kokai E, Devergne O, Marx N, Wirth T. Epstein-Barr virus-induced gene-3 is expressed in human atheroma plaques. Am J Pathol (2009) 175:440–7.10.2353/ajpath.2009.08075219556516
85. Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab (2010) 21:33–40.10.1016/j.tem.2009.07.00519854061
86. Sanchez V, Dong JJ. Alteration of lipid metabolism in cells infected with human cytomegalovirus. Virology (2010) 404:71–7.10.1016/j.virol.2010.04.02620552728
87. Machesky NJ, Zhang G, Raghavan B, Zimmerman P, Kelly SL, Merrill AH, Jr et al. Human cytomegalovirus regulates bioactive sphingolipids. J Biol Chem (2008) 283:26148–60.10.1074/jbc.M71018120018644793
88. Huang B, Chen Y, Xie Q, Lin G, Wu Y, Feng Y, et al. CagA-positive Helicobacter pylori strains enhanced coronary atherosclerosis by increasing serum OxLDL and HsCRP in patients with coronary heart disease. Dig Dis Sci (2011) 56:109–14.10.1007/s10620-010-1274-620503072
89. Louw L, Seedat R, Claassen A. HPV-induced recurrent laryngeal papillomatosis: fatty acid role-players. Asia Pac J Clin Nutr (2008) 17(Suppl 1):208–11.18296339
90. Kelesidis T, Currier JS. Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection. Endocrinol Metab Clin North Am (2014) 43:665–84.10.1016/j.ecl.2014.06.00325169560
91. Popper K. The Logic of Scientific Discovery. London, UK: Routledge Classics (2002).
92. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med (2007) 356:2388–98.10.1056/NEJMsa05393517554120
93. A report of the Surgeon General. The Health Consequences of Smoking: 50 Years of Progress. Rockville: US Department of Health and Human Services (2014).
94. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol (2014) 34:509–15.10.1161/ATVBAHA.113.30015624554606
95. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA (2010) 303:2043.10.1001/jama.2010.65020501926
96. Gao WQ, Feng QZ, Li YF, Li YX, Huang Y, Chen YM, et al. Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound. BMC Cardiovasc Disord (2014) 14:60.10.1186/1471-2261-14-6024886532
97. Madan M, Bishayi B, Hoge M, Messas E, Amar S. Doxycycline affects diet- and bacteria-associated atherosclerosis in an ApoE heterozygote murine model: cytokine profiling implications. Atherosclerosis (2007) 190:62–72.10.1016/j.atherosclerosis.2006.02.02616563401
98. Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J (2008) 22:2416–26.10.1096/fj.07-10272318326786
99. Cotter PD, Stanton C, Ross RP, Hill C. The impact of antibiotics on the gut microbiota as revealed by high throughput DNA sequencing. Discov Med (2012) 13:193–9.22463795
100. Tulstrup MV, Christensen EG, Carvalho V, Linninge C, Ahrné S, Højberg O, et al. Antibiotic treatment affects intestinal permeability and gut microbial composition in Wistar rats dependent on antibiotic class. PLoS One (2015) 10:e0144854.10.1371/journal.pone.014485426691591